



Program

Monday, October 24

Nagano

Session 1: Novel Viral Platforms

Chairpersons: Brian Lichty, Takafumi Nakamura

8:30-8:55

INV02: Brian D Lichty

McMaster University

Projecting STING Agonism from Oncolytic Viruses

8:55-9:10

INV03: Takafumi Nakamura

Division of Molecular Medicine, School of Medicine, Tottori University Faculty of Medicine, Japan

Next-generation oncolytic vaccinia viral platform

9:10-9:25

INV04: William Jia

Virogin Biotech Ltd, Canada

New Strategies for oncolytic virotherapy: Turning anti-viral immunity to anti-tumor

9:25-9:40

Oral 1: Michael Franti

Boehringer Ingelheim, USA

Path to the clinic: preclinical pharmacokinetics, biodistribution, and immunogenicity strategies to support first-in-man studies with VSV-GP oncolytic virus

9:40-9:55

Oral 2: Xinzhi Zou

Stanford University, USA

Rewiring oncogenic signaling to therapeutic viral activation

Sponsored by Turnstone Biologics

9:55-10:25

Coffee Break

Monday,
October 24

Monday, October 24

Nagano

Session 2: Clinical Trials

Chairpersons: E. Antonio Chiocca, Toshiyoshi Fujiwara

10:25-10:40	<p>INV05: Toshiyoshi Fujiwara <i>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan</i> Multidisciplinary oncolytic virotherapy for esophageal cancer patients unfit for standard treatments</p>	
10:40-10:55	<p>INV06: Ken-ichiro Kosai <i>Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medicine and Dental Sciences, Japan</i> First-in-human phase I clinical trial of Surv.m-CRA-1 (survivin-responsive conditionally replicating adenovirus)</p>	
10:55-11:10	<p>Oral 3: James Clubb <i>Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland</i> Ad5/3-E2F-D24-TNFa-IRES-IL2 (TILT-123) from preclinical development to phase I clinical trials</p>	
11:10-11:25	<p>Oral 4: Hiroshi Nakashima <i>Brigham and Women's Hospital and Harvard Medical School, USA</i> Transcriptome analysis of brain tumor tissues in phase I clinical trial of rQNestin34.5v2 (CAN-311)</p>	*No on-demand
11:25-11:40	<p>Oral 5: Ulrich M. Lauer <i>University Hospital Tuebingen, Germany</i> Immunovirotherapy as a novel add-on treatment in NUT carcinoma</p>	
12:15-13:15	Lunch (provided)	

Monday,
October 24



Program

Monday, October 24

Nagano

Session 3: Combination Therapies

Chairpersons: Shane Foo, Masatoshi Tagawa

- 13:30-13:55** **INV07: Shane Foo**
The Institute of Cancer Research, UK
 Oncolytic Maraba Virus primes specific anti-tumour T cell responses in melanoma with therapy dependent on tumour size and enhanced by addition of checkpoint blockade
- 13:55-14:10** **INV08: Masatoshi Tagawa**
Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Japan
 An MDM2 inhibitor induces expression of NFI, a cellular factor for adenovirus replications, and augmented cytotoxic effects of adenoviruses through DNA damage pathways
- 14:10-14:25** **INV09: Balveen Kaur**
Department of Neurosurgery, University of Texas, USA
 Metabolic strategy to terminate glioblastoma: HSV-P10 reverses Warburg effect and potentiates anti-tumor response in conjunction with CD73 blockade
- 14:25-14:40** **INV10: Grant McFadden**
Center for Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, USA
 A novel anti-cancer co-therapy using nuclear export inhibitor Selinexor plus oncolytic Myxoma virus
- 14:40-14:55** **Oral 6: Charlotte A Wynn**
Leeds Institute of Medical Research at St. James's, University of Leeds, UK
 Impact of Hepatitis C Virus on Reovirus Immunotherapy for Hepatocellular Carcinoma
- 14:55-15:10** **Oral 7: Yasuo Nagai**
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
 Combination therapy with telomerase-specific oncolytic adenovirus and PD-L1 blockade against gemcitabine-resistant pancreatic cancer

Monday, October 24

Nagano

Afternoon Session 1

Chairperson: Yozo Nakazawa

- 15:20-16:20** **INV11: Shinichi Makita** *No on-demand
Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
 CAR T-cell therapy for B-cell non-Hodgkin lymphoma

Sponsored by Daiichi Sankyo Co., Ltd.

16:20-16:50

Break

Program

Monday, October 24

Nagano

17:00-19:15 Poster Session

Monday, October 24

Asama

19:30 Banquet



Monday,
October 24